Cargando…
Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis
INTRODUCTION: Bronchiectasis is an increasingly common chronic inflammatory airway disease. We evaluated secondary safety outcomes in a comparative effectiveness study of chronic inhaled corticosteroids (ICS) and macrolide monotherapy in bronchiectasis patients. METHODS: We conducted a retrospective...
Autores principales: | Henkle, Emily, Daley, Charles L., Curtis, Jeffrey R., Chan, Benjamin, Aksamit, Timothy R., Winthrop, Kevin L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899493/ https://www.ncbi.nlm.nih.gov/pubmed/35265701 http://dx.doi.org/10.1183/23120541.00786-2020 |
Ejemplares similares
-
192. Tolerability Outcomes of Multi-drug Antibiotic Treatment for Pulmonary Nontuberculous Mycobacterial Disease due to Mycobacterium avium Complex in U.S. Medicare Beneficiaries with Bronchiectasis
por: Ku, Jennifer, et al.
Publicado: (2021) -
Inhaled Corticosteroids and Bronchiectasis: Friend or Foe?
por: Martinez-Garcia, Miguel Angel
Publicado: (2023) -
Validity of Diagnosis Code–Based Claims to Identify Pulmonary NTM Disease in Bronchiectasis Patients
por: Ku, Jennifer H., et al.
Publicado: (2021) -
The Role of Macrolides in Noncystic Fibrosis Bronchiectasis
por: Figueiredo, Bruna de Campos Guimarães e, et al.
Publicado: (2011) -
Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis
por: Kwok, Wang Chun, et al.
Publicado: (2023)